Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Phase II/III Clinical Study to Evaluate the Efficacy and Safety of GenaKumab in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.

NCT05925452 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05925452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05925452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Phase II/III Clinical Study to Evaluate the Efficacy and Safety of GenaKumab in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase
Not applicable
Overall status
Recruiting
Start date
December 1, 2023
Completion date
June 29, 2028
Enrollment
290 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

active systemic juvenile idiopathic arthritis